https://sciex.com/content/SCIEX/na/us/en


MultiOmics Research For the Study of Placental Development

Aug 20, 2015 | Blogs, Life Science Research, Proteomics | 0 comments

A recent study by Katy Williams (UCSF), Christie Hunter (SCIEX), and Andrew Olsen (Advaita) used the iPathwayGuide within the OneOmics cloud computing environment to help understand how placental development can go awry during certain pregnancy complications such as pre-eclampsia.

In this pilot study, the researchers studied cytotrophoblast differentiation. Cytotrophoblasts are the cells that are mainly responsible for establishing an anchor between the developing embryo and placenta with the uterine wall. The researchers compared cytotrophoblasts from the primary culture at both 2nd trimester and full term. SWATH proteomics data acquired using a SCIEX TripleTOF® 6600 System were analyzed in OneOmics using iPathwayGuide to identify differentially regulated proteins and their associated pathways, biological processes, and molecular functions. The proteomics data were then compared with RNASeq transcriptomics data acquired using an Illumina HiSeq System. Both the proteomics data and transcriptomics data were correlated using the OneOmics Platform and iPathwayGuide in the cloud. This meta-analysis allowed the researchers to discover common pathways and processes between the data sets as well as those only observed in the proteomic or transcriptomic datasets alone.

The pilot study helped to illuminate the biological significance of multiple proteins and pathways and provided an effective pipeline for taking raw data to biological answers.

See the complete study by viewing a 10 minute mini webinar. If you’d like to get a demo of the OneOmics Project, just comment below and we’ll be in touch. 

 

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial